Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Mazdutide

A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

Innovent · Phase 2 · Completed · Enrollment 328

NCT04904913

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
IBI362 high dosen/rn/rn/rn/r
IBI362 low dosen/rn/rn/rn/r
placebon/rn/rn/rn/r
IBI362 moderate dosen/rn/rn/rn/r
IBI362 extra high dosen/rn/rn/rn/r

Not shown

  • IBI362 high dose: endpoint not reported
  • IBI362 low dose: endpoint not reported
  • placebo: endpoint not reported
  • IBI362 moderate dose: endpoint not reported
  • IBI362 extra high dose: endpoint not reported